Bexarotene derivatives modify responses in acute myeloid leukemia
G. Hadwiger, O. di Martino, M. A. Ferris, A. Vu, T. E. Frederick, G. R. Bowman, P. Ruminski, C. Wagner, J. S. Welch
This study screens bexarotene derivatives to identify compounds with enhanced anti-leukemic activity in AML, finding that dual RARA/RXRA activity and structural modifications affect potency and metabolic stability.
bioRxiv · May 17, 2021 · PreprintCancer Biology